Nastech Licenses RNAi IP From City of Hope to Develop siRNA Drugs

Nov 08, 2006

NEW YORK (GenomeWeb News) — Nastech Pharmaceutical has licensed RNAi intellectual property and technology from the City of Hope, the company said today.

Nastech licensed City of Hope’s Dicer-Substrate RNA patents and technology in order to develop short-interfering RNA-based drugs for diseases related to protein over-production.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Make Sense of It All

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

Variations on Results

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

This Week in Nature

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

Of Many Minds

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.

Featured White Papers

The Ultimate Guide to Mouse Clinical Trials

Highly Resolved Separation of DNA Fragments on the Fragment Analyzer

How to Perform Successful CRISPR Experiments

High Throughput RT-qPCR for Gene Expression Analysis

Jun

19

Featured Webinar

RNA in situ Hybridization: The Next Generation of Immunohistochemistry?

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Main menu